Pancreatic Cancer Research

ResearcherGarvan Institute of Medical ResearchActive in the last 2 years

Marie Ranson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5570-9645; OpenAlex author ID A5061261970. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers

Papers 8

  1. Localized Delivery of Anti-CD40/PD-1 Immunotherapy via a Polymeric Implant is Efficacious, Remodels the Tumor Immune Microenvironment and Improves Safety in a … Co-author DOI 10.1002/adhm.202503780↗
  2. Selective Urokinase Inhibition Plus Chemotherapy: A Novel Approach to Pancreatic Cancer Treatment via Enhanced Antitumor Immunity and Decreased Metastasis. Co-author DOI 10.1053/j.gastro.2025.07.021↗
  3. Neoadjuvant chemotherapy induces transient, regimen-specific immune–stromal reprogramming in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.09.07.749769↗
  4. Gut microbial diversity is preserved through localised chemo-immunotherapy delivery in a KPC mouse model of pancreatic cancer. Co-author DOI 10.1016/j.jconrel.2025.114143↗
  5. Enhancing pancreatic cancer immunotherapy: Leveraging localized delivery strategies through the use of implantable devices and scaffolds. First author DOI 10.1016/j.jconrel.2024.07.023↗
  6. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU). Co-author DOI 10.3389/fimmu.2022.1060957↗
  7. The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets. Last author DOI 10.3390/biom12020152↗
  8. SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. Co-author DOI 10.1038/onc.2017.63↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kara L. Vine · 5 shared papers, 2017–2026 · strength 1.17
  2. Elahe Minaei · 4 shared papers, 2024–2026 · strength 1.11
  3. Samantha J. Wade · 3 shared papers, 2025–2026 · strength 0.83
  4. Ashna A. Kumar · 2 shared papers, 2022–2026 · strength 0.52
  5. S. M. Zahid Hosen · 2 shared papers, 2022–2026 · strength 0.39
  6. Minoti Vivek Apte · 2 shared papers, 2022–2026 · strength 0.39
  7. Tony Pang · 2 shared papers, 2022–2026 · strength 0.39
  8. Jeremy S. Wilson · 2 shared papers, 2022–2026 · strength 0.39
  9. Chamini Jayamali Perera · 2 shared papers, 2022–2026 · strength 0.39
  10. Koroush Shahsavar Haghighi · 1 shared paper, 2026 · strength 0.24
  11. Eileen Mary O'Reilly · 1 shared paper, 2026 · strength 0.24
  12. David Goldstein · 1 shared paper, 2022 · strength 0.13
  13. Zhihong Xu · 1 shared paper, 2022 · strength 0.13
  14. Mohammad Ali Moni · 1 shared paper, 2022 · strength 0.13
  15. Steve Gallinger · 1 shared paper, 2022 · strength 0.13
  16. Faiyaz Notta · 1 shared paper, 2022 · strength 0.13
  17. Claire Vennin · 1 shared paper, 2017 · strength 0.06
  18. Marina Pajic · 1 shared paper, 2017 · strength 0.06
  19. David Herrmann · 1 shared paper, 2017 · strength 0.06
  20. Mark J. Cowley · 1 shared paper, 2017 · strength 0.06
  21. Darren N. Saunders · 1 shared paper, 2017 · strength 0.06
  22. James R. W. Conway · 1 shared paper, 2017 · strength 0.06
  23. Australian Pancreatic Cancer Genome Initiative · 1 shared paper, 2017 · strength 0.06
  24. Jennifer P. Morton · 1 shared paper, 2017 · strength 0.06
  25. Paul Timpson · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.